Ironwood Pharmaceuticals to Present New Data on Once-Weekly

– Data from pivotal Phase III STARS study in short bowel syndrome with intestinal failure accepted as late-breaker oral presentation on May 21 at 10:30 am ET –


– Findings from the STARS...

Related Keywords

Washington , United States , Boston , Massachusetts , China , Japan , Switzerland , Michael Shetzline , Ironwood Pharmaceuticals Nasdaq , Linkedin , Exchange Commission , Astrazeneca , A National Survey Analysis , Ironwood Pharmaceuticals , Ironwood Pharmaceuticals Inc , Center Trial , Nasdaq , Drug Administration , Disease Week , Apraglutide Once Weekly , Short Bowel Syndrome , Intestinal Failure , Global Phase , Placebo Controlled Trial , Bowel Morphology , Motility Assessed , Short Bowel Syndrome Intestinal Failure , Colon In Continuity Treated , Support Weaning , Clinical Benefit , Improved Patient Reported Outcomes , Long Acting Glucagon Like , Analog Apraglutide , Increased Oral Intake , Improved Energy , Carbohydrate Absorption , Gastric Emptying , Healthy Individuals , Single Center Trial , Bowel Syndrome , Functional Constipation , World Prescribing Patterns , Pediatric Patients , Irritable Bowel Syndrome , National Survey Analysis , Acute Graft Versus Host Disease , Common Adverse Reactions , Prescribing Information , Boxed Warning , Annual Report , Markets ,